Abeona Therapeutics reports FY 2025 net gain of $152.4M from PRV sale
Abeona Therapeutics (NASDAQ:ABEO) on Wednesday reported financial results for the full year ended December 31, 2025, and provided operational updates centered on the commercial launch of its lead gene therapy ZEVASKYN.
The company generated total revenue of $5.8 million for the year, while recording a net gain of $152.4 million from the sale of a Rare Pediatric Disease Priority Review Voucher.
Cash and short-term investments stood at $191.4 million at year-end.
Meanwhile, ZEVASKYN, approved by the U.S. Food and Drug Administration for the treatment of recessive dystrophic epidermolysis bullosa, began its commercial launch in the fourth quarter of 2025.
The first commercial patient was treated in December, marking the transition from clinical development to revenue-generating operations.
Treatments and patient biopsies resumed in early 2026 following a temporary manufacturing shutdown.
Elsewhere, the company noted rising selling, general and administrative expenses associated with commercialization activities, as well as $1.5 million in cost of sales related to initial production batches.
More from United States
AbbVie revenue increases 10.3% to $17.4 billion in third quarter
Sensient Q3 revenue rockets 10.6% to $455.8 million
Cameco Q3 adjusted loss reaches CA$2 million as uranium output falls
Kite Realty Q3 loss narrows to $13.3 million as NOI grows
Largo cuts 2026 vanadium production outlook to 9,500–10,500 tonnes
nVent Q3 sales jump 44% as shares fall despite higher revenue
